As I see it

Share this article:
Along with high-level apologies for competency failures in the Office of the Attorney General, VA hospitals, FEMA, FBI and many others, we may add the FDA, previously the world's “gold standard” of health product regulators.

Not only did it fail to protect America from tainted pet food, simultaneously claiming it didn't regulate that industry and that it applies the same inspection force to pet food as to human food, but in March the FDA's new commissioner was caught presenting false testimony to Congress while under oath.

Andrew von Eschenbach apparently didn't know that his staff-prepared testimony contained 11 false statements about the approval of Sanofi-Aventis' Ketek, so congressional investigators went after his staff instead of the occupant of the desk.

In an unprecedented letter to Michael Leavitt, head of the FDA's parent department, House Energy and Commerce Committee chair and chair of the Subcommittee on Oversight and Investigations asked for all documents used in preparing the tainted testimony, and to interview everyone involved.

As in most of the wider government scandals already in the headlines, this one didn't involve allegations of criminal intent—just the everyday competency that employers (taxpayers) expect of our employees (the government).

As former Tennessee senator and potential presidential candidate Fred Thompson wrote in an op-ed: “A big part of the problem is our outmoded civil-service system that makes it too hard to hire good employees and too hard to fire bad ones. The bureaucracy has become gargantuan, making accountability and reform very difficult.”

Recent efforts to reform the FDA show the alarming wisdom in those words.
 
Dickinson is editor of Dickinson's FDA Webview (fdaweb.com)

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications